One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects

• Published in: International Journal of Infectious Diseases Vol. 138; pp. 73 - 80
• Main Authors: Lovell, Jonathan F., Miura, Kazutoyo, Baik, Yeong Ok, Lee, Chankyu, Lee, Jeong-Yoon, Park, Young-Shin, Hong, Ingi, Lee, Jung Hyuk, Kim, Taewoo, Seo, Sang Hwan, Kim, Jae-Ouk, Song, Manki, Kim, Chung-Jong, Choi, Jae-Ki, Kim, Jieun, Choo, Eun Ju, Choi, Jung-Hyun
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.01.2024; Elsevier BV; Elsevier
• Subjects: COVID-19; Durability; Humoral immunity; Infectious and parasitic diseases; Liposome; RBD; RC109-216; SARS-CoV-2; Vaccine; COVID-19; SARS-CoV-2; RBD; Liposome; Durability; Vaccine; Humoral immunity

•EuCorVac-19 is a vaccine that displays the SARS-CoV-2 receptor binding domain on immunogenic liposomes.•As part of a Phase 2 trial, antibodies were tested 6 and 12 months after vaccination.•Median antibody half-life was 52 days in the early period, and 130 days in the late period.•Median neutralizi...